Single dyes typically exhibit limited light absorption in dye-sensitized solar cells (DSSCs). Thus, cosensitization using two or more dyes to enhance light-harvesting efficiency has been explored; however, the aggregation of dyes can adversely affect electron injection capabilities. This study focused on the design and synthesis of three dyes with a common carbazole donor for DSSCs: DZ102, TZ101, and JM102. JM102 broadens the absorption spectrum by replacing the benzoic acid electron acceptor of TZ101 with acetylenic benzoic acid. A cosensitized DSSC device based on CO-1 [DZ102:TZ101 = 1:1 (50 μM:50 μM)] achieved a short-circuit current density of 19.4 mA/cm² and a power conversion efficiency of 10.9%. For the first time, the molecular interactions between the dyes in the photoanode were demonstrated using cyclic voltammetry, which revealed the presence of intermolecular forces. Adsorption kinetics further indicated that these forces promoted the self-assembly of dyes during adsorption, which resulted in a cosensitization adsorption amount greater than the sum of the individual dye adsorptions. This study provides novel insights into the selection of cosensitizing dyes for DSSCs.

26 Apr 2013·Investigative Opthalmology & Visual ScienceQ2 · MEDICINE

Circulating Mononuclear Progenitor Cells: Differential Roles for Subpopulations in Repair of Retinal Vascular Injury

Q2 · MEDICINE

ArticleOA

Author: Caballero, Sergio ; Miller, Leonard P. ; Bhatwadekar, Ashay ; Hazra, Sugata ; Grant, Maria B. ; Chang, Lung-Ji ; Li Calzi, Sergio ; Paradiso, Linda J. ; Kern, Timothy S.

PURPOSEWe examined effect on retinal vascular homing of exogenous CD34(+) and CD14(+) progenitor cells using mouse models of chronic (streptozotocin [STZ]-induced diabetes) and acute (ischemia-reperfusion [I/R]) ocular vascular injury.METHODSSTZ-treated mice of short or long duration (≤4, ≥11 months) diabetes, along with age- and sex-matched controls, were given intravitreous injections of human CD34(+) and CD14(+) cells isolated from healthy or diabetic donors alone or in combination. I/R injured mice were given diabetic or nondiabetic CD34(+) cells with mesenchymal stem cells (MSCs) or diabetic CD34(+) cells manipulated by ex vivo fucosylation with ASC-101. Injected cells were localized by fluorescent immunocytochemistry, and the degree of retinal vascular colocalization quantified morphometrically. Permeability was assessed by fluorescent albumin leakage.RESULTSDiabetic CD14(+) cells associated with vessels to a greater degree than diabetic CD34(+) cells. Vascular permeability was reduced only by nondiabetic cells and only at the highest number of cells tested. Diabetic CD34(+) cells consistently demonstrated reduced migration. There was a 2-fold or 4-fold increase over control in the specific localization of diabetic CD34(+) cells within the vasculature when these cells were co-administered with MSCs or ex vivo fucosylated prior to injection, respectively.CONCLUSIONSDiabetic CD14(+) cells, unlike diabetic CD34(+) cells, retain robust homing characteristics. CD34(+) or CD14(+) subsets rather than whole bone marrow or peripheral blood cells may prove more beneficial in autologous cell therapy for diabetics. Co-administration with MSCs or ex vivo fucosylation may enhance utility of CD34(+) cells in cell therapy for diabetic ocular conditions like macular ischemia and retinal nonperfusion.

100 Deals associated with TZ-101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graft vs Host Disease	Phase 2	United States	Targazyme, Inc.	-
Hematopoietic stem cell transplantation	Discovery	United States	Targazyme, Inc.	25 Oct 2016
Hematologic Neoplasms	Discovery	United States	Targazyme, Inc.	27 Aug 2012
Stroke	Discovery	United States	Targazyme, Inc.	27 Aug 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TZ-101

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation